Shailender Bhatia
University of Washington · 335 works · 27,508 citations · h-index 58
Top works
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- Treatment of metastatic melanoma: an overview.
- Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
- Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma–Specific Survival Independent of Stage
- Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
- 1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
- Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
- Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
- 545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)
- Age-Specific Incidence of Melanoma in the United States